AustralianSuper Pty Ltd Cuts Position in DaVita Inc. $DVA

AustralianSuper Pty Ltd cut its holdings in DaVita Inc. (NYSE:DVA) by 8.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 118,037 shares of the company’s stock after selling 10,261 shares during the quarter. AustralianSuper Pty Ltd’s holdings in DaVita were worth $15,684,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Assenagon Asset Management S.A. lifted its holdings in DaVita by 1,951.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 68,408 shares of the company’s stock worth $9,089,000 after buying an additional 65,074 shares in the last quarter. Norges Bank purchased a new position in DaVita in the second quarter valued at $32,986,000. Edgestream Partners L.P. acquired a new stake in shares of DaVita during the 2nd quarter worth about $6,375,000. Rakuten Investment Management Inc. acquired a new stake in DaVita during the third quarter worth approximately $19,875,000. Finally, Nordea Investment Management AB lifted its position in DaVita by 1.8% in the third quarter. Nordea Investment Management AB now owns 286,585 shares of the company’s stock valued at $37,864,000 after acquiring an additional 5,193 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Up 1.2%

DVA stock opened at $107.16 on Friday. The stock has a market capitalization of $7.57 billion, a price-to-earnings ratio of 11.04, a price-to-earnings-growth ratio of 0.65 and a beta of 0.99. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $179.60. The stock’s fifty day simple moving average is $113.80 and its 200-day simple moving average is $125.54.

DaVita (NYSE:DVA) last released its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.17 by ($0.66). The company had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.43 billion. DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.DaVita’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.59 earnings per share. As a group, analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on DVA shares. UBS Group reiterated a “buy” rating on shares of DaVita in a research note on Monday, December 15th. TD Cowen reissued a “hold” rating on shares of DaVita in a report on Monday, November 3rd. Zacks Research raised DaVita from a “strong sell” rating to a “hold” rating in a report on Friday, November 28th. Wall Street Zen downgraded shares of DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Finally, Truist Financial cut their price target on DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a research note on Monday, January 5th. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $145.60.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.